63 results
8-K
EX-99.1
HEPA
Hepion Pharmaceuticals Inc
2 Oct 23
Hepion Pharmaceuticals Announces $5.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market under Nasdaq Rules
6:29pm
, hepatocellular carcinoma (“HCC”), and other chronic diseases, today announced that it has entered into a securities purchase agreement with a healthcare-focused
8-K
EX-99.1
HEPA
Hepion Pharmaceuticals Inc
24 Jul 23
Regulation FD Disclosure
4:04pm
from “From NASH to HCC: current concepts and future challenges”, Anstee et al. (2019) NASH is Driving a Healthcare Crisis The Need and Opportunity
8-K
EX-1.1
HEPA
Hepion Pharmaceuticals Inc
21 Jul 23
Entry into a Material Definitive Agreement
4:41pm
and Cosmetic Act (21 U.S.C. §§ 301 et seq.); (ii) all applicable federal, state, local and all applicable foreign healthcare related fraud and abuse laws … to healthcare fraud and abuse, including but not limited to 18 U.S.C. Sections 286 and 287, the healthcare fraud criminal provisions under the U.S. Health
8-K
EX-99.1
HEPA
Hepion Pharmaceuticals Inc
22 May 23
Regulation FD Disclosure
1:05pm
and future challenges”, Anstee et al. (2019) 6 NASH is Driving a Healthcare Crisis The Need and Opportunity NAFLD non-alcoholic fatty liver disease
8-K
EX-99.1
xzig9de6o lh7f
17 Oct 22
Regulation FD Disclosure
5:13pm
8-K
EX-99.1
zark1zraye1k7 zrmty
10 Jan 22
Regulation FD Disclosure
6:02am
8-K
EX-99.1
v816 xi5ed14
30 Sep 21
A BETTER APPROACH TO DRUG DEVELOPMENT FOR LIVER DISEASES October 202 1 | INVESTOR PRESENTATION smart drug smart technology smart development
5:22pm
8-K
EX-99.2
iwca1ej
13 Sep 21
Regulation FD Disclosure
8:28am